Q4 FY2025 · ended Dec 31, 2025 · Revenue $0 · Filed Mar 24, 2026
BioCardia, Inc. (BCDA) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$1.7 million. As of Jun 30, 2026 it held $4.1 million in cash and investments and $293,000 in total debt.
Revenue
$0
Net income
$-1.61M
+21.3% vs year-ago quarter
Operating cash flow
$-1.74M
-5.2% vs year-ago quarter
Free cash flow
$-1.74M
-5.2% vs year-ago quarter
EPS
$-0.21
+47.5% vs prior quarter
Dividend per share
None
Shares outstanding
15.14M
+161.0% vs year-ago quarter
Net cash
$3.82M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- BCDA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Sunnyvale, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 925741
- Former names
- Tiger X Medical, Inc. (until Oct 17, 2016); Cardo Medical, Inc. (until May 25, 2011); CLICKNSETTLE COM INC (until Oct 20, 2008); NAM CORP (until Mar 29, 2000)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 |
| Operating income | -$1.6M | -$2.3M | -$2.0M | -$1.5M | -$2.1M |
| Net income | -$1.6M | -$2.3M | -$2.0M | -$1.5M | -$2.0M |
| Diluted EPS | — | -$0.21 | — | — | -$0.40 |
| Operating cash flow | -$1.7M | -$1.7M | -$2.5M | -$1.7M | -$1.6M |
| Free cash flow | -$1.7M | -$1.7M | -$2.5M | -$1.7M | -$1.6M |
| Total assets | $4.8M | $1.7M | $3.4M | $6.1M | $2.1M |
| Total liabilities | $2.1M | $2.8M | $2.5M | $3.5M | $4.0M |
| Stockholders' equity | $2.7M | -$1.1M | $895,000 | $2.6M | -$1.9M |
| Cash and investments | $4.1M | $951,000 | $2.5M | $5.3M | $980,000 |
| Total debt | $293,000 | $412,000 | $528,000 | $638,000 | $745,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 19, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Other events
|
Oct 7, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Other events
|
Oct 1, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Other events
|
Sep 23, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Other events
|
Sep 21, 2026 | Sep 21, 2026 |
| 8-K |
Current report
Other events
|
Sep 10, 2026 | Sep 10, 2026 |
All 1002 BioCardia, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.